Explore the Agenda

Inaugural AI & mRNA Design Day

8:00 am Check In & Coffee

8:50 am Chair’s Opening Remarks

Fractional Chief AI Officer, Abogen Inc.

Leveraging Deep Learning Models & Generative AI to Optimize the Design of Stable & Effective mRNA Sequences

9:00 am The Next Frontier for mRNA Therapeutics – AI Applications in Design, Delivery & Manufacturing

Fractional Chief AI Officer, Abogen Inc.
  • Using ML/AI in mRNA sequence design
  • Applying ML/AI in delivery design and optimization
  • Leveraging ML/AI in protein design
  • Automation, process optimization, and digitization – Enabling efficiency but also feeding the Design Build-Test-Learn virtuous cycle

9:30 am Sequencing-Powered Data & AI for Next-Generation mRNA Therapeutic Design

AI Design Lead, Eclipse Bioinnovations
  • RNA-centric sequencing datasets capture unique features needed for predictive mRNA design models
  • Foundation models enable UTR optimization and enhanced structural stability to improve therapeutic efficacy
  • Integrated Design-Make-Test workflows provide a robust lab-in-the-loop engine for mRNA therapeutic development

10:00 am Deep Learning Guided Optimization of Translation Efficiency for mRNA Vaccine Development

Head of mRNA Design Data Science, Sanofi
  • Delivered mRNA vaccines benefit from a high protein yield to stimulate an effective immune response
  • Training RiboNN, a deep learning model, to predict translation efficiency — a major determinant of protein yield — among numerous cell types
  • RiboNN can be used to guide the design of translation-optimized mRNA therapeutics

10:30 am Morning Break & Networking

Harnessing mRNA Language Models to Improve mRNA Design for Vaccine Applications & Biomanufacturing

11:30 am Using mRNA Language Models for Efficient Coding Sequence Design

Professor, Kitasato University
  • AI, especially biological language models, accelerates mRNA design
  • mRNA design methods for heterologous expression can be used for biomanufacturing and biopharmaceuticals
  • Feedback from experimental data is important for improving mRNA design

12:00 pm Evolving the mRNA Alphabet: Foundational Models for Vaccine Design & Optimization

Computational Science Lead, Sanofi
  • Highlighting key foundational mRNA language models
  • Illustrating end-to-end mRNA vaccine optimization
  • Discussing De novo mRNA vaccine design

12:30 pm Lunch Break & Networking

Boosting mRNA Design Capabilities & Data Set Generation from Structure to Function Across Therapeutic Applications

1:30 pm Advancing mRNA Stability Modeling & Design

Computation Scientist, Moderna
  • Highlighting RNA sequence space
  • Presenting key design features
  • Showcasing new structure metric and stability predictor

2:00 pm Biologically Informed AI models for mRNA design

Director, Australian National University
  • Domain-specific knowledge can facilitate more efficient training strategies and help improve the accuracy of AI models
  • Illustrating this with examples of AI models for mRNA property prediction and design
  • Discussing how to expand this strategy to other properties in the context of mRNA therapeutics

2:30 pm AI‑Driven Design of Selectively Translated mRNA Therapeutics for In Vivo CAR-T

Co-Founder & Head of Platform, Kernal Biologics Inc.
  • Presenting cell selective translation
  • Demonstrating effective dataset generation
  • Showcasing training models and designing mRNA

3:00 pm Chair’s Closing Remarks

Fractional Chief AI Officer, Abogen Inc.

3:15 pm End of AI & mRNA Design Day

3rd Next Generation mRNA Delivery Day

8:00 am Check In & Coffee

8:50 am Chair’s Opening Remarks

Chief Technology Officer, Land Tx

Innovating mRNA-LNP Designs to Achieve Effective & Targeted Payload Delivery for Vaccine & Therapeutic Applications

9:00 am Novel Approach with Bispecific Antibodies to Simplify Conjugation & Improve Receptor Engagement for Effective Targeted Payload Delivery

Vice President of Platform, Mote Therapeutics
  • Leveraging bispecific antibodies’ dual specificity to boost engagement with extrahepatic tissues and optimize payload delivery
  • Removing complex chemical conjugation process by leveraging bispecific antibodies to connect LNPs with cell-specific receptors
  • Overcoming traditional conjugation challenges to support easier large-scale production of targeted LNP and accelerate translation from research to clinic

9:30 am Minimalist Nanoparticle Designs for RNA Medicines

Chief Executive Officer, Zipcode Bio
  • Leveraging artificial intelligence in mRNA and cirRNA development
  • Presenting a novel delivery strategy with fresh data insights

10:00 am Round Table Discussion: A Scientific Outlook – Overcoming Challenges of Novel LNP Chemistries & Formulations to Achieve a Successful Patent Outcome for mRNA Delivery

Principal Scientist, GSK US
  • Dissecting a patent and presenting an overview about the process
  • What can be patented in an LNP?
  • Designing LNPs with specific patent claims in mind
  • How do I know that I have enough information to file a patent?

10:30 am Morning Break & Networking

Business Development Manager, Flashpoint Therapeutics

Beyond the LNP: Unlocking Non-Viral Delivery Methods to Optimize Delivery & Therapeutic Performance

11:30 am Advancing RNA-Based Therapeutics Using a Structural Nanomedicine Approach

  • Pioneering a structural nanomedicine platform designed to optimize delivery and therapeutic performance across mRNA and other therapeutic modalities
  • Demonstrating examples of enhanced mRNA delivery and efficiency using structural nanomedicine, outperforming conventional LNP
  • Highlighting recent program updates with expanded non-clinical data in oncology and CRISPR-based gene editing applications

12:00 pm Optimizing mRNA Delivery with Targeted Elastin-Like Polypeptide-Based LENN Formulations

Professor, Purdue University
  • LENN comprised of elastin-like polypeptide-epidermal growth factor fusion proteins (ELP-EGF) and cyclodextrin-peptide conjugates form stable mRNA complexes that efficiently deliver their cargo to the cytosol of EGFR+ bladder tumor cells in vitro and in vivo
  • Multiple reaction monitoring HPLC-MS lipidomics analysis, pharmacologic inhibition, and EGF blockade experiments indicate that EGF-bearing mRNA LENN enter EGFR+ cells via clathrin-mediated endocytosis, with no significant changes to other lipid pathways that would indicate off-target effects or immune responses
  • Addition of 10% glycerol and lyophilization enables the long-term storage of mRNA LENN complexes, with full retention of activity after rehydration

12:30 pm Lunch Break & Networking

Overcoming the Barriers of Delivery Chemistry to Achieve Organ Specific Targeting & Offer a Competitive Edge in the mRNA Market

1:30 pm Oral mRNA Delivery to the Gastrointestinal Tract

Co- Founder & Chief Scientific Officer, Pacira Pharmaceuticals Inc
  • Outlining challenges of delivering mRNA to the gastrointestinal tract
  • Presenting a strategy for iterating LNPs in vivo to deliver to the gastrointestinal tract
  • Demonstrating an application of oral mRNA=LNP in mouse models

2:00 pm Low-Inflammatory RNABL Delivery Enables Organ-Specific Therapeutic RNA Applications

Principal Scientist, Tiba Biotech LLC
  • Introducing non-inflammatory, biodegradable RNABL dendritic molecules for nucleic acid complexation and in vivo delivery
  • Showcasing Organ tunability and safety profile of RNABL formulations
  • Demonstrating successful therapeutic applications in animal models

2:30 pm Chair’s Closing Remarks

Chief Technology Officer, Land Tx

2:35 pm End of Next Generation mRNA Delivery Day